Given this, we expressed this panel of EGFR VUS in three EGFR mutant NSCLC cell lines, PC9, HCC4006, and HCC827, and assessed cell viability after 144 h by treating cells with increasing concentrations of erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.